NASDAQ: ASLN - ASLAN Pharmaceuticals Limited

六个月盈利: 0%
股息率: 0.00%
部门: Healthcare

促销时间表 ASLAN Pharmaceuticals Limited

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co.

更多详情
, Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2018-05-04
ISIN US04522R1014
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://aslanpharma.com
Цена ао 0.6
每日价格变化: 0% (0.6)
每周价格变化: 0% (0.6)
每月价格变化: 0% (0.6)
3个月内价格变化: 0% (0.6)
六个月内的价格变化: 0% (0.6)
每年价格变化: -4% (0.625)
3年内价格变化: -22.67% (0.7759)
5年内价格变化: -72.09% (2.15)
10年价格变化: 0% (0.6)
年初以来价格变化: 0% (0.6)
所有参数

低估

姓名 意义 年级
P/S 4.41 4
P/BV -3.98 0
P/E 0 0
EV/EBITDA -1.35 0
全部的: 4.25

效率

姓名 意义 年级
ROA, % -179.56 0
ROE, % 332.81 10
全部的: 3.33

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.6183 10
全部的: 9.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 4.45 1
盈利能力 Ebitda, % 2792.47 10
盈利能力 EPS, % 1015.89 10
全部的: 8.2
更多详情

机构 体积 分享, %
BVF Inc. 1049999 13.82
UBS Group AG 625000 8.23
Citadel Advisors Llc 482963 6.36
Shay Capital LLC 400000 5.26
Sio Capital Management, LLC 254150 3.34
Renaissance Technologies, LLC 172801 2.27
Parkman Healthcare Partners LLC 110658 1.46
Landscape Capital Management LLC 83259 1.1
Millennium Management LLC 80362 1.06
Waterfront Wealth, Inc. 40941 0.54



导师 职称 支付 出生年份
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. Founder, CEO & Executive Director N/A 1973 (52 年)
Mr. Kiran Kumar Asarpota COO & Head of Finance N/A 1979 (46 年)
Mr. Ben Goodger General Counsel N/A 1963 (62 年)
Mr. Stephen Doyle Chief Business Officer N/A 1973 (52 年)
Dr. Alexandre Kaoukhov M.D. Chief Medical Officer N/A 1974 (51 年)
Charlie Hsu Investor Relations Director N/A
Chi-Chin Wang IR & Corporate Development Director N/A

地址: Singapore, Singapore, 3 Temasek Avenue - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://aslanpharma.com